November 8, 2012 / 8:33 PM / 5 years ago

BRIEF-Balance seen in efficacy, hypoglycemia with Novo's degludec insulin - chair FDA panel

Nov 8 (Reuters) - Novo Nordisk A/S : * Hypoglycemia risk of Novo nordisk’s degludec insulin in trials did

not appear significantly higher or lower than oher insulins -- chair of FDA

advisory panel * Balance seemed reasonable between efficacy and hypoglycemia in studies of

degludec - chair of FDA advisory panel * 24-hr half life of degludec makes it unique in terms of long, stable

duration, dosing flexibility - chair of FDA advisory panel

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below